NCT05855083招募中2 期
A Phase 2 Study Evaluating the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Narsoplimab in Pediatric Patients (28 Days to ≤ 18 Years of Age.) With High-Risk Hematopoietic Stem Cell Transplant Thrombotic Microangiopathy
适应症
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 入组人数
- 18
- 试验地点
- 16
- 主要终点
- 100-day survival rate following high-risk HSCT-TMA diagnosis.
研究概览
简要总结
The purpose of this study is to evaluate the safety and efficacy of narsoplimab in pediatric patients with thrombotic microangiopathies (TMA) following hematopoietic stem cell transplant (HSCT).
详细描述
This is a Phase 2, uncontrolled, single-dosing regimen study in pediatric patients from 28 days to less than 18 years of age with high risk HSCT-TMA. At least 4 patients will be required from each of 3 age cohorts:
28 days to <2 years of age, 2 years to <12 years of age, and 12 years to <18 years of age.
Treatment will be for 8 weeks and patients will be followed for up to 52 weeks.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 28 Days 至 17 Years（Child）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Age at least 28 days and less than 18 years prior to informed consent (Visit 0).
- •Have informed consent from at least one parent or legal guardian as required by local law and regulation. Patient informed consent will be required if the patient has reached the local legal age of majority.
- •Assent from patients as required by local law and regulation.
- •Have received an allogeneic hematopoietic stem cell transplant for the treatment of benign or malignant disease.
- •Have a diagnosis of HSCT-TMA defined as meeting both of the following criteria:
- •Platelet count < 50,000/mL or a decrease in platelet count > 50% from the highest value obtained following transplant.
- •Evidence of microangiopathic hemolysis (presence of schistocytes, serum lactate dehydrogenase [LDH] > upper limit of normal ([ULN], or haptoglobin < lower limit of normal [LLN])
- •Have at least one of the following HSCT-TMA high-risk criteria:
- •HSCT-TMA persistence > 2 weeks following modification of calcineurin inhibitors or sirolimus OR
- •Have evidence of high-risk HSCT-TMA defined as at least one of the following:
- •Spot protein/creatinine ratio > 2 mg/mg
- •Serum creatinine > 1.5 x the creatinine level prior to TMA development
- •Biopsy-proven gastrointestinal TMA
- •TMA-related neurological abnormality
- •Pericardial or pleural effusion without alternative explanation
- •Pulmonary hypertension without alternative explanation
- •Have Grade III or Grade IV graft-versus-host disease (GVHD) or, in the opinion of the Investigator, risk for development of Grade III or Grade IV GVHD if immunosuppression were to be modified
- •Have elevated serum C5b-9 (> 244 ng/mL)
- •If sexually active and of childbearing potential (for female pediatric patients, defined as starting at onset of menses), must agree to practice a highly effective method of birth control throughout study drug treatment and for at least 12 weeks after the last dose of study drug, such method of birth control defined as one that results in a low failure rate (i.e., less than 1% per year) when used consistently and correctly, such as implants, injectables, combined oral contraceptives, some intrauterine devices, sexual abstinence (abstinence is acceptable when it is in line with the patient's preferred and usual lifestyle and is defined as complete abstinence of sexual intercourse, not periodic abstinence or withdrawal), or vasectomized partner.
- •Male patients must be willing to avoid fathering children for at least 12 weeks following the last dose of study medication.
排除标准
- •All treatments for HSCT-TMA are allowed except eculizumab, ravulizumab, and defibrotide within 3 months prior to informed consent, unless failure of therapy can be documented.
- •a. Patients may not be on eculizumab, ravulizumab, or defibrotide for any indication at screening.
- •Have Shiga toxin-producing Escherichia coli haemolytic uraemic syndrome (STEC-HUS). Test results obtained within 28 days prior to informed consent may be used.
- •Have ADAMTS13 activity < 10%. Test results obtained within 28 days prior to informed consent may be used.
- •Have a severe, uncontrolled systemic bacterial or fungal infection requiring antimicrobial therapy, or a severe uncontrolled viral infection (as determined by the investigator); prophylactic antimicrobial therapy administered as standard of care is allowed.
- •Have malignant hypertension (blood pressure [BP] > 99th percentile plus 5 mmHg with bilateral hemorrhages or "cotton-wool" exudates on fundoscopic examination).
- •Due to conditions other than HSCT-TMA, have a poor prognosis with a life expectancy of less than 3 months in the opinion of the Investigator.
- •If pregnant or lactating.
- •Have received treatment with an investigational drug or device within 4 weeks of entering study.
- •Have abnormal liver function tests defined as alanine aminotransferase (ALT) or aspartate aminotransferase (AST) > 5 times ULN within 28 days prior to informed consent.
- •Have a positive test by antigen or polymerase chain reaction (PCR) for human immunodeficiency virus (HIV), if negative within 28 days prior to informed consent, the test does not need to be repeated.
- •Patient or one or more of the patient's parents or legal guardians are is an employee or an immediate family member of Omeros, the Clinical Research Organization (CRO), an Investigator, or a study staff member.
- •Have a known hypersensitivity to any constituent of the product.
- •Presence of any condition that the Investigator believes would put the patient at risk.
结局指标
主要结局
100-day survival rate following high-risk HSCT-TMA diagnosis.
时间窗: 100 days
Percentage of patients alive at 100 days following the diagnosis of high-risk HSCT-TMA
次要结局
- Number of participants with treatment-emergent adverse events assessed by CTCAE v5.0(52 weeks)
- Percentage of patients meeting protocol definition of clinical response(52 weeks)
- 52 week survival rate following high-risk HSCT-TMA diagnosis(52 weeks)
- Overall survival following the diagnosis of high-risk HSCT-TMA(52 weeks)
- Pharmacokinetics (PK) of multiple-dose administration of OMS721(52 weeks)
- Presence of anti-drug antibody (ADA)(52 weeks)
研究者
研究点 (16)
Loading locations...
相似试验
已完成
2 期
An Efficacy and Safety Study of Niraparib in Men With Metastatic Castration-Resistant Prostate Cancer and DNA-Repair AnomaliesProstatic NeoplasmsNCT02854436Janssen Research & Development, LLC289
撤回
1 期
Natalizumab in Recurrent, Refractory or Progressive Pulmonary Metastatic OsteosarcomaPulmonary Metastatic Osteosarcoma (pOS)NCT03811886Case Comprehensive Cancer Center20
招募中
2 期
A Study to Evaluate the Safety and Pharmacokinetics of Eflapegrastim in Pediatric Participants With Solid Tumors or Lymphomas and Treated With Myelosuppressive ChemotherapySolid TumorsLymphomaNCT04570423Spectrum Pharmaceuticals, Inc40
进行中（未招募）
1 期
Safety and Dose Finding Study of Neratinib in Children and Young Adults With Cancer That Has Returned or Not Responded to TreatmentSolid TumorLymphomaLeukemiaCentral Nervous System TumorNCT02932280Memorial Sloan Kettering Cancer Center14
已完成
2 期
Study of Nivolumab and Relatlimab in Patients With Microsatellite Stable (MSS) Advanced Colorectal CancerMicrosatellite Stable (MSS) Colorectal AdenocarcinomasColorectal AdenocarcinomaNCT03642067Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins59